Genmab — December 2014
-
-
Faldt lige over denne: http://www.haematologica.org/content/early/2014/11/10/haematol.2014.117531
-
http://www.pharmafile.com/news/161848/bristol-myers-squibb-licences-innate-pharma-iph2102 BMS er helt fremme i front med immunforsvars regulerende antistoffer.
-
In summary, this preclinical evaluation suggest that a further
increase in the potency of MM treatment strategies can be designed by combining DARA
with the immune modulatory agent LEN as well as with the KIR-blocking antibody IPH2102,
whereby synergistic elimination of MM tumors by NK cells may be achieved. -
Hej alle
-
Tillykke med jeres genmabgevinster i år. Det har været et helt fantastisk år for os alle. (for 3 år i træk nu). Havde ihvertald aldrig selv drømt at jeg i en alder af 25 kunne have en aktie der gav mig så mange penge på så kort tid. Men vi kan takke hinanden for det. Vi leverer alle herind et fantastisk arbejde mht. at finde hver en lille relevant genmab nyhed
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind